Blay J-Y - Department of Research (CRCL), Centre Léon Bérard

基本信息

浏览量：65

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 119 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

89P IMmunotherapy response associated clinical and biological PREdictive factors in advanced SARComas: A retrospective multicenter study

M. Fazel, R. Varnier,J-Y. Blay, M. Brahmi

ESMO Open (2024)

引用0浏览0引用

Novel trial designs for patients with gastrointestinal stromal tumor

C. Serrano, S. Rothschild, G. Villacampa, M. C. Heinrich, S. George,J. -Y. Blay, J. K. Sicklick, G. K. Schwartz, S. Rastogi,R. L. Jones, P. Rutkowski, N. Somaiah,

ESMO OPENno. 1 (2024): 102218-102218

引用0浏览0WOS引用

55O IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

A. Le Cesne, S. Chabaud, O. Bouche, N. Penel, M. Brahmi, M. Toulmonde, E. Bompas, F. Bertucci, L. Chaigneau, W. Lahlou, B. Landi, B. Verret,

ESMO Open (2024)

引用0浏览0引用

59MO COTESARC – A multicentre, phase I-II clinical trial evaluating the combination of MEK and PDL-1 inhibitors in patients (pts) with advanced soft tissue sarcoma (STS): Results from complex (CG) and simple genomic (SG) STS cohorts

A. Dufresne, M. Brahmi, C. Cropet, R. Bahleda, S. Watson, P. Pautier, I.L. Ray-Coquard, I. Aerts, F. Duffaud, A-S. Defachelles, B. Verret, G. Fournier Garin,

ESMO Open (2024)

引用0浏览0引用

VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

A. Le Cesne, C. Schiffler, O. Bouche, M. Brahmi, F. Duffaud, M. Toulmonde, B. Landi, W. Lahlou, D. Pannier, E. Bompas, F. Bertucci, L. Chaigneau,

Annals of Oncology (2024)

引用0浏览0引用

62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutations: ctDNA analysis from INTRIGUE

J-Y. Blay, R.L. Jones, H. Gelderblom, S. George, P. Schöffski,M. von Mehren, J.R. Zalcberg,Y-K. Kang, A.R. Abdul Razak, J.C. Trent, S. Attia,A. Le Cesne,

ESMO Open (2024)

引用0浏览0引用

Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC plus series of 330 patients over 13 years

J. Y. Blay, C. Tlemsani, M. Toulmonde, A. Italiano, M. Rios, E. Bompas, T. Valentin, F. Duffaud,L. R. Le Nail, S. Watson, N. Firmin, P. Dubray-Longeras,

EUROPEAN JOURNAL OF CANCER（2024）

引用0浏览0引用

54O Health state impacts of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma: SPEARHEAD-1 cohort 1

M. Wagner, C. Lunt, D. Araujo,J-Y. Blay, M. Druta, S. Attia, C.M. Valverde Morales, K. Ganjoo, S.M. Schuetze, E. Van Winkle, P. Bayer, J. Bai,

ESMO Open (2024)

引用0浏览0引用

52O Resistance to imatinib induced by treatment interruption in advanced GIST: Long-term outcome of the randomized BFR14 study

J-Y. Blay, Q. Devin, F. Duffaud, M. Toulmonde, N. Firmin, O. Collard, E. Bompas, B. Verret, I.L. Ray-Coquard, S. Salas, C. Henon, C. Honoré,

ESMO Open (2024)

引用0浏览0引用

206P WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)

J-Y. Blay,A. Hackshaw,C. Le Tourneau, J. Geissler, A. Ferro, E. Schirgruber, O. Skatkova, R. Dienstmann

Annals of Oncology (2023): S264-S265

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn